№6(6) 2023

DOI 10.37219/2528-8253-2023-6-72

Deineko IV, Kovtunenko OV
TREATMENT STRATEGY IN PATIENTS WITH LOCALLY ADVANCED MALIGNANT THYROID TUMOURS
WITH UPPER RESPIRATORY TRACT STENOSIS
Deineko Illia V
Dnipropetrovsk Regional Clinical Hospital named after. І.І. Mechnikov
Endocrine surgery center
Head of the center
Candidate of Medical Sciences
Email: ilyadey@gmail.com
ORCID ID: https://orcid.org/0000-0002-3120-0983
Scopus Author ID: 57277633600
Kovtunenko Oleksandr V
Dnipro State Medical University
Professor of the Department of Otorhinolaryngology
Doctor of Medical Sciences, Professor
Email: lor@dsma.dp.ua
ORCID ID: https://orcid.org/0000-0002-0562-7684
Scopus Author ID: 57215498685

Abstract

Topicality: Malignant thyroid tumours account for more than 3% of all human cancers. Highly differentiated forms of early stage (T1-3) thyroid cancer occur in more than 90% of cases, and they don’t cause much difficulty for the surgeon. But in recent years, the number of advanced malignant thyroid tumours of T4a-b stages with invasion or compression of the upper respiratory tract, recurrent nerves, has been increasing very rapidly. Most often, these are tumours with medium and low histological differentiation, which sharply worsens the prognosis of treatment of such patients.

Objective: To determine treatment tactics and improve its quality in patients with locally advanced malignant thyroid tumours with compression or invasion into the upper airways.

Materials and methods: From 2004 to 2023, 2300 patients with malignant thyroid tumours were treated in the endocrine surgery department of the I.I. Mechnikov Regional Clinical Hospital. All patients were divided into 2 groups according to the TNM classification of AJCC 8th edition according to the extent of the primary tumour: Group 1 – without invasions (T1-3) and group 2 – advanced invasive tumours (T4a-b). In the 1st group (T1-3) were included 2130 patients, in the 2nd group (T4a-b) – 170 patients with locally advanced malignant thyroid tumours, which was 7.4% of all examined patients. 149 out of 170 patients in the T4a-b group underwent radical surgical interventions as part of complex treatment, 21 patients with advanced stage T4b tumours underwent non-radical cytoreductive surgery.

Results: In 84 (49.4%) patients in the T4a-b group, there was tumour invasion into the trachea and in some cases into the cricoid cartilage and structures of the larynx, 20 (11.8%) patients had invasion of the recurrent nerves, which also worsened the patency of the upper respiratory tract (URT). 25 (14.7%) patients had stenosis of the URT due to their external compression by a large dense tumour mass. In 20 (11.8%) patients with invasion of the URT, the stenosis was aggravated by external compression of the tumour. The majority – 149 patients of T4a-b group – underwent radical surgeries: extended thyroidectomies, lymphodissections of the neck, if necessary with upper sternotomy, Crile procedure, resection of the oesophagus, recurrent nerve and other affected organs and structures of the neck and upper mediastinum. 21 patients with extremely advanced cases with inoperable tumours underwent non-radical, cytoreductive surgery, in 11 patients with a permanent tracheostomy. All patients in the T4a-b group received various adjuvant radiotherapy or radioiodine therapy, in some cases polychemotherapy and prolonged screening. In the group of radically operated patients, the mortality rate was 31.5%; recurrences, most often to regional lymph nodes, were observed in 38.3% of cases. At the same time, in the group of patients who underwent non-radical cytoreductive surgical interventions as part of complex treatment, the mortality rate was 85.7%.

Conclusions: Maximum radical, “aggressive” extended operations with tumour removal within healthy tissues with simultaneous partial resections of the upper respiratory tract as part of complex treatment significantly improves survival rates, quality and life expectancy of patients.

Keywords: locally advanced malignant thyroid tumours, tumour invasion, upper airway stenosis, surgical tactics, treatment results.

References

  1. Horgan D, Führer-Sakel D, Soares P, Alvarez CV, Fugazzola L, Netea-Maier RT, Jarzab B, Kozaric M, Bartes B, Schuster-Bruce J, Dal Maso L, Schlumberger M, Pacini F. Tackling Thyroid Cancer in Europe-The Challenges and Opportunities. Healthcare (Basel). 2022 Aug 25;10(9):1621. doi: 10.3390/healthcare10091621.
  2. Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C, Vaccarella S. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022 Apr;10(4):264-272. doi: 10.1016/S2213-8587(22)00035-3.
  3. Nabhan F, Dedhia PH, Ringel MD. Thyroid cancer, recent advances in diagnosis and therapy. Int J Cancer. 2021 Sep 1;149(5):984-992. doi: 10.1002/ijc.33690.
  4. Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C, Vaccarella S. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022 Apr;10(4):264-272. doi: 10.1016/S2213-8587(22)00035-3.
  5. Guda BB, Pushkarev VM, Kovalenko AE, Pushkarev VV, Kovzun ОI, Tronko MD. Molecular genetic mechanisms of the pathogenesis of thyroid malignant tumors (review of literature and own data, part 1). Endokrynologia. 2019;24(1):53-65. doi: https://doi.org/10.31793/1680-1466.2019.24-1.53. [Article in Ukrainian].
  6. Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, Dal Maso L. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021 Apr;9(4):225-234. doi: 10. 1016/S2213-8587(21)00027-9.
  7. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013:2013:965212. doi: 10.1155/2013/965212.
  8. Soheylizad M, Khazaei S, Jenabi E, Delpisheh A, Veisani Y. The Relationship Between Human Development Index and Its Components with Thyroid Cancer Incidence and Mortality: Using the Decomposition Approach. Int J Endocrinol Metab. 2018 Oct 20;16(4):e65078. doi: 10.5812/ijem.65078.
  9. Xua J, Liaob Zh, Lid J-J, Wud X-F, Zhuangd S-M. The Role of Tracheostomy in Anaplastic Thyroid Carcinoma. World J Oncol. 2015 Feb;6(1):262-264. doi: 10.14740/wjon899w.
  10. Wang H, Tao M, Zhang N, Luo L, Li D, Zou H, Zhou Y, Liang S. Bronchoscopic interventions combined with percutaneous modalities for the treatment of thyroid cancers with airway invasion. Eur Arch Otorhinolaryngol. 2015 Feb;272(2):445-51. doi: 10.1007/s00405-014-2963-0.
  11. Hölting T, Meybier H, Buhr H. [Problems of tracheotomy in locally invasive anaplastic thyroid cancer]. Langenbecks Arch Chir. 1989;374(2):72-6. doi: 10.1007/BF01261613. [Article in German].
  12. Bortz MD, Kuchta K, Winchester DJ, Prinz RA, Moo-Young TA. Extrathyroidal extension predicts negative clinical outcomes in papillary thyroid cancer. Surgery. 2021 Jan;169(1):2-6. doi: 10.1016/j.surg.2020.04.003.
  13. Krasnoselsky MV, Bely OM, Verbitsky MV. [Personalisation of reconstructive-plastic surgeries for locally advanced thyroid cancer]. Ukrainian journal of radiology and oncology. 2017;XXV(annex 2);32-6. [Article in Ukrainian].
  14. Radjabova ZA-G, Kotov MA, Artemiev SS, Radjabova MA. [Surgical treatment of locally advanced thyroid cancer (literature review)]. Head and neck tumors. 2018;2(8):62-7. [Article in Russian].
  15. Chen AM, Luo XY. [Clinical analysis of differentiated thyroid carcinoma invading larynx and tracheal esophagus]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 May 20;31(10):802-803. doi: 10.13201/j.issn.1001-1781.2017.10.016. [Article in Chinese].
  16. Gupta V, Rao C, Raju KVVN, Nemade H, Dasu S, Jayakarthik Y, Shukla S, Rao TS. Tracheal/Laryngeal Infiltration in Thyroid Cancer: a Single-Centre Experience. Indian J Surg Oncol. 2020 Mar;11(1):75-79. doi: 10.1007/s13193-019-00994-7.
  17. Brauckhoff M, Dralle H. [Extrathyroidal thyroid cancer: results of tracheal shaving and tracheal resection]. Chirurg. 2011 Feb;82(2):134-40. doi: 10.1007/s00104-010-1975-6. [Article in German].
  18. Brooks JA, Abdelhamid Ahmed AH, Al-Qurayshi Z, Kamani D, Kyriazidis N, Hammon RJ, Ma H, Sritharan N, Wasserman I, Trinh LN, Iwata AJ, Saito Y, Soylu S, Randolph GW; R Score Research Group. Recurrent Laryngeal Nerve Invasion by Thyroid Cancer: Laryngeal Function and Survival Outcomes. Laryngoscope. 2022 Nov;132(11):2285-2292. doi: 10.1002/lary.30115
  19. Miyamaru S, Murakami D, Nishimoto K, Kodama N, Tashiro J, Miyamoto Y, Saito H, Takeda H, Ise M, Orita Y. Optimal Management of the Unilateral Recurrent Laryngeal Nerve Involvement in Patients with Thyroid Cancer. Cancers (Basel). 2021 Apr 28;13(9):2129. doi: 10.3390/cancers13092129.
  20. Iwaki S, Maeda T, Saito M, Otsuki N, Takahashi M, Wakui E, Shinomiya H, Morimoto K, Inoue H, Masuoka H, Miyauchi A, Nibu KI. Role of immediate recurrent laryngeal nerve reconstruction in surgery for thyroid cancers with fixed vocal cords. Head Neck. 2017 Mar;39(3):427-431. doi: 10.1002/hed.24627.
  21. Liu JW, Chen C, Loh EW, Chu CC, Wang MY, Ouyang HJ, Chang YT, Zhuang WZ, Chou CW, Huang DJ, Lee CH, Yen Y, Tam KW. Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2018 May;34(5):795-803. doi: 10.1080/03007995.2017.1368466.
  22. Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Materazzi G, Antonelli A. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes. Cancer Manag Res. 2019 Aug 21:11:7893-7907. doi: 10.2147/CMAR.S127848.
  23. Schmid KW, Synoracki S, Dralle H, Wittekind C. Proposal for an extended TNM classification of thyroid carcinoma: Commentary on deficits of the 8th edition of the TNM classification. Pathologe. 2019 Jun;40(Suppl 1):18-24. doi: 10.1007/s00292-018-0418-x.